SYK

Business Context and Reporting Period

Company: Stryker Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2001
Business Overview: Stryker develops, manufactures, and markets specialty surgical and medical products, including orthopaedic implants, MedSurg equipment, and physical therapy services. Operations are segmented into Orthopaedic Implants, MedSurg Equipment, and Other (Physical Therapy Services and corporate).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the nine-month period. Growth was driven by a 10-11% increase in unit volume and 3% price increases, partially offset by a 2-3% decline due to foreign currency exchange rates.
• Profitability: Net earnings rose 21% for the quarter and 23% for the nine-month period. Diluted EPS increased 20% and 22%, respectively.
• Segment Performance:
  • Orthopaedic Implants: Sales up 10% (quarter) and 8% (nine months), driven by reconstructive and trauma products.
  • MedSurg Equipment: Sales up 17% (quarter) and 18% (nine months), driven by powered surgical instruments and endoscopic systems.
  • Physical Therapy Services: Sales up 18% (quarter) and 25% (nine months) due to new centers and higher revenue from existing ones.
• Cost Structure: Cost of sales as a percentage of sales increased slightly (36.9% vs. 35.7% prior year) primarily due to the reclassification of freight revenue and shipping costs. SG&A expenses as a percentage of sales decreased slightly due to the same reclassification and lower discount expenses on receivables.
• Debt Reduction: Total debt declined by $204.8 million during the first nine months of 2001 due to repayments exceeding borrowings.

Guidance, Outlook, and Risks

• Regulatory Milestone: On October 17, 2001, the FDA granted Humanitarian Device Exemption (HDE) status for the OP-1 Implant, the first BMP approved in the U.S. Commercial launch in the U.S. was expected to commence in the fourth quarter of 2001.
• Accounting Changes: The company noted the upcoming implementation of FASB Statements No. 141 and 142 effective January 1, 2002. This will eliminate goodwill amortization, expected to increase net earnings by approximately $10 million ($0.05 per diluted share) in 2002. Initial impairment tests for goodwill will be performed in 2002.
• Liquidity: Management believes cash on hand and operating cash flows are sufficient to fund operations and debt repayments. An additional $256.7 million of borrowing capacity remains available under existing credit facilities.
• Risks: Forward-looking statements are subject to risks including changes in economic conditions, foreign exchange markets, financial markets, and the competitive environment. Foreign currency translation losses of $8.4 million were recorded in equity for the nine-month period.

Investor Verification Checklist

• Freight Revenue Classification: Verify the impact of recording freight revenue in net sales (2001) versus offsetting cost of sales (2000) on gross margin comparisons.
• Foreign Currency Impact: Assess the sensitivity of international sales (approx. 35% of total) to exchange rate fluctuations, which negatively impacted reported sales by $53.2 million in the first nine months.
• Goodwill Impairment: Monitor the results of the initial goodwill impairment tests required in 2002 under FASB 142, as the company has not yet determined the potential effect on earnings.
• OP-1 Commercialization: Track the commercial uptake of the OP-1 Implant following its U.S. launch, noting the company's caution regarding significant sales impact in 2001.
• Debt Maturities: Review the schedule of current maturities of long-term debt, which are projected to increase to $168.2 million in 2003 and $203.1 million in 2004.